Be sure to visit us in person at RSNA 2022, November 27–30 in Chicago at McCormick Place, where we’ll have our team on hand to answer questions, and discuss your imaging needs. Also, at booth number #6638, we will be presenting MILabs’ latest advancements in synergistic translational PET-SPECT-Optical-CT imaging and high-performance clinical SPECT imaging (G-SPECT*). If you would like to schedule a meeting with our team, please click below. For a quick preview of MILabs’ latest imaging products, watch our video.
Innate defense regulators (IDRs) are synthetic host-defense peptides (HDPs) with broad-spectrum anti-infective properties, including immunomodulatory, anti-biofilm, and direct antimicrobial activities. A lack of pharmacokinetic data about these peptides hinders their development. To investigate the pharmacokinetics of IDR-1018, a well-characterized IDR molecule, 67Ga radiolabelled IDR-1018 was imaged in mice using VECTorCT technology by MILabs. Uptake analysis demonstrated that subcutaneous local delivery of this IDR peptide is the best administration route, reaching sufficient concentrations to exert a direct antimicrobial effect on many common bacterial pathogens. Published in Eur J Pharm Biopharm, Oct. 2022, DOI: https://pubmed.ncbi.nlm.nih.gov/36028151/
PSMA–targeted radiohybrid (rh) ligand [177Lu]Lu-rhPSMA-7.3 has recently been assessed for pre-therapeutic dosimetry in prostate cancer patients. In comparison to [177Lu]Lu-PSMA I&T, [177Lu]Lu-rhPSMA-7.3 resulted in a significantly improved tumor dose but also higher kidney accumulation. The rhPSMA ligand with the best pharmacokinetics for 177Lu-radioligand therapy was identified using MILabs VECTor SPECT-PET-CT. [177Lu]Lu-rhPSMA-10.1 has favorable pharmacokinetics in mice. Clinical tests are needed to see if high tumor uptake and low uptake in nontarget tissues apply also in patients. Published in the J. Nucl. Med., Oct. 2022, DOI: https://jnm.snmjournals.org/content/63/10/1489
MILabs Users’ meeting 2022
Our first face-to-face users’ meeting since the pandemic was held in October right after the EANM 2022, close to our headquarter in Houten, the Netherlands. We devoted about half of the meeting to talks from within our user’s community to other users about what they were able to learn and achieve with the MILabs imaging systems, and the other half to demonstrations of our equipment, and perspectives on PET, SPECT, CT as well as 2D/3D/4D bioluminescence and fluorescence imaging portfolio. Therefore, we had many highly useful talks from both our users and the MILabs team aiming to help others get more out of their instruments.
Thanks to our fantastic user community participating in and contributing to the meeting, making it such a great event.
Join our team: open vacancies
MILabs seeks talented individuals to further scale-up its organization.
*G-SPECT has received all approvals for preclinical large animal applications and is commercially available for preclinical use. G-SPECT development, market clearance procedures, and certification for clinical use are in the final stages.